PeriodontitisNCT02403960
Probiotic Use in Chronic Periodontitis Patients
A study testing probiotic in people with Periodontitis, run by Cukurova University at 1 site in Turkey (Türkiye).
Trial summary
Aim: to evaluate the additional effects of the 12 weeks usage of a Streptococcus containing probiotic tablet after scaling and rootplaning compared to a placebo tablet. Materials and methods: 48 periodontitis patients were included in this double-blind, placebo-controlled trial. Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Periodontitis
- What is being tested?
- probiotic
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Jun 2010to May 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- healthy, non-institutionalized male or female patients,
- at least 35 years of age,
- a minimum of 3 natural teeth in every quadrant and
- previously untreated moderate to severe periodontitis
Who cannot join
- received antibiotics for any purpose within 6 months prior to entering the study or suffering from a disease condition that would typically require antibiotic prophylaxis before dental treatment,
- a history of diabetes, rheumatic fever, liver or kidney disease, neurological deficiencies, or use of medication which may affect periodontal tissue (for example: phenytoin, cyclosporin, chronic use of non-steroidal anti-inflammatory drugs),
- pregnancy,
- acute oral lesions or necrotizing ulcerative periodontitis and
- dental personnel
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of a Streptococcus Probiotic in Periodontal Therapy: a Randomized Controlled Trial
Aim: to evaluate the additional effects of the 12 weeks usage of a Streptococcus containing probiotic tablet after scaling and rootplaning compared to a placebo tablet.
Materials and methods: 48 periodontitis patients were included in this double-blind, placebo-controlled trial. After scaling and rootplaning, they were given patients used either a placebo (SRP) or probiotic tablet (SRP + P), 2 times a day for 12 weeks. Clinical and microbiological parameters were studied recorded up to 24 weeks after scaling and rootplaning.
Read the detailed description
Materials and methods This double-blind, placebo-controlled, randomized (1:1 ratio) controlled trial with two parallel arms involved 48 patients with advanced adult periodontitis. They were recruited at the periodontology department of the Cukurova university, Turkey. All patients referred for periodontal treatment were screened for eligibility.The project was approved by the ethical committee for clinical trials of the Cukurova University in Turkey with number . No changes in the trial design were made after approval by the Ethical Committee.
Sample size calculation and randomization Power analysis prior to the start of the study was difficult since no previous randomized controlled trials on this study product were available. The sample size was determined. Pocket probing depth was taken into account, with an expected difference of 0.82mm and a standard deviation of 0.61mm. It was calculated that 10 patients were needed in each group to provide 80% power with an alpha of 0.05 . Despite this low number and taking into consideration studies comparing the adjunctive effect of antibiotics to scaling and rootplaning, it was decided to include 24 patients in each group.
Randomization of the patients was done by block randomization . The study coordinator distributed the coded bottles to the examiner at baseline, 4 weeks and 8 weeks visit. Except for the study coordinator, all patients and study personnel were blinded to the study group allocation. Before sending the data to the biostatistician, the code was broken to group the patients to the proper groups.
Treatment protocol Patients fulfilling the eligibility criteria were asked to participate in the study and after approval to sign an informed consent. Baseline examination included full-mouth probing pocket depth , gingival recession and bleeding on probing measured at six sites per tooth. Additionally the plaque en gingival indexes were noted. The full-mouth plaque index was recorded.After baseline periodontal examination and microbial analysis, an oral hygiene instruction was given (toothbrush, interdental brush). Initial periodontal therapy consisted of a full-mouth one-stage disinfection approach . All clinical procedures were performed by the same periodontist . The patient was asked to rinse for 2 minutes with a 0.12% chlorhexidine solution without alcohol . Scaling and rootplaning were performed on 2 consecutive days using an ultrasonic scaler under 0.12% chlorhexidine irrigation and with hand instruments. All mucosal surfaces were afterwards disinfected and the tongue was brushed for 1 minute. Besides, the participants were randomized over the 2 treatment groups: control or probiotic group.The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months. The participants in the control group were asked to do the same with a placebo tablet. All patients were instructed to use the tablets after brushing their teeth in the morning and in the evening. The probiotic and placebo tablets were identical in shape, texture, taste and composition except that Streptococcus were added for the probiotic tablet. All patients were supplied with the same toothpaste . It was asked not to use any probiotic containing products during the course of the study. Neither was it allowed to use drugs with anti-inflammatory properties, chlorhexidine or other mouthrinses during the study.
At designated time points, follow-up visits were planned. 30 days and 60 days after initiation of the therapy clinical evaluation and microbial analysis were performed. 90 days and 180 days after the initial treatment all baseline parameters were recorded .
Outcomes variables of interest Primary outcome measures The primary response variable was Probing pocket depth. All examinations were performed with a North Carolina periodontal probe .
Secondary outcome measures The secondary response variables were recession, clinical attachment level , Bleeding, Gingival index, Plaque index and microbial parameters.
Sub-analyses were performed on these outcome variables taking into account the initial Pocket. A pocket was considered moderate if its initial Pocket was between 4 and 6 mm and deep if ≥7 mm. "Risk for disease progression" was defined at patient level. The "need for surgery" outcome measure was calculated. A site was considered as "in need for surgery" if the Pocket was ≥6 mm or 5 mm and Bleeding positive. A tooth was considered in need for surgery if it had at least one site in need for surgery. A patient was considered in need or surgery if at least one tooth was in need for surgery.
Microbiological samples were collected of supragingival and subgingival plaque, saliva and the tongue. Pooled supragingival plaque samples were taken with the aid of curettes at the four single-rooted teeth with the deepest initial pocket in each quadrant. Before sampling, the sites were isolated from saliva with the aid of cotton rolls and then dried with compressed air. All supragingival plaque from these sites was dispersed. Samples were dispersed using a vortex mixer and immediately frozen at -20°C until analysis. On the same teeth pooled subgingival plaque samples were collected per site. After 10 s, the samples were transferred to a sterile Eppendorf tube, as described Saliva samples were obtained by collecting unstimulated saliva in a sterile cup. Finally the biofilm of the tongue was collected with a cotton swab. These were wiped 10 times over the tongue starting from the tongue dorsum.
Processing of the microbial samples After finishing the study, the frozen samples were send on dry ice to the department of Periodontology , these were immediately frozen at -80°C upon arrival. each sample was later defrosted and centrifuged at 13.000g. Bacterial DNA was extracted . A quantitative assay was performed to quantify certain bacteria.
- Conditions
- Periodontitis
- Being tested
- probiotic, placebo
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
probioticDietary supplement
the patients used probiotic tablets in addition to scaling and root planning
placeboDietary supplement
the patients used placebo tablets in addition to scaling and root planning
| Study group | Role | What they receive |
|---|---|---|
| probiotic | Active comparator | The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months. Receives: Dietary Supplement: probiotic |
| placebo | Placebo comparator | The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months. Receives: Dietary Supplement: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
probing pocket depth
Measured: 24 weeks
Secondary outcomes (6)
Recession
Recession as measured in millimeters.
Measured: 24 weeks
clinical attachment level
clinical attachment level as measured in millimeters
Measured: 24 weeks
Bleeding on probing
Bleeding as measured in presence or absence of bleeding on probing the sulcus
Measured: 24 weeks
Gingival Index
Measured: 24 weeks
Plaque Index
Measured: 24 weeks
microbial counts of bacteria
microbial counts as measured in colony forming units
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2015 (estimated)
- Study startJun 2010
- Primary completionNov 2010
- Study completionMay 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cukurova University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Onur Ozcelik, Cukurova University
- Investigators
- Onur Ozcelik, Study chair, CU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02403960
- Sponsor's protocol ID
- CukurovaU3
- Status last verified
- Oct 2015
- First submitted
- 16 Mar 2015
- Last updated
- 2 Nov 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, Slomka V, Quirynen M, Alkaya B, Teughels W. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015 Nov;42(11):1032-41. doi: 10.1111/jcpe.12464. Epub 2015 Nov 29.
PubMed 26427036
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of a Streptococcus Probiotic in Periodontal Therapy: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02403960
- Acronym / sponsor ID
- CukurovaU3
- Conditions
- Periodontitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Cukurova UniversityUniversity, hospital or other
- Study start
- Jun 2010
- Primary completion
- Nov 2010 (actual)
- Study completion
- May 2011 (actual)
- First posted
- 31 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim: to evaluate the additional effects of the 12 weeks usage of a Streptococcus containing probiotic tablet after scaling and rootplaning compared to a placebo tablet.
Materials and methods: 48 periodontitis patients were included in this double-blind, placebo-controlled trial. After scaling and rootplaning, they were given patients used either a placebo (SRP) or probiotic tablet (SRP + P), 2 times a day for 12 weeks. Clinical and microbiological parameters were studied recorded up to 24 weeks after scaling and rootplaning.
Detailed description
Materials and methods This double-blind, placebo-controlled, randomized (1:1 ratio) controlled trial with two parallel arms involved 48 patients with advanced adult periodontitis. They were recruited at the periodontology department of the Cukurova university, Turkey. All patients referred for periodontal treatment were screened for eligibility.The project was approved by the ethical committee for clinical trials of the Cukurova University in Turkey with number . No changes in the trial design were made after approval by the Ethical Committee.
Sample size calculation and randomization Power analysis prior to the start of the study was difficult since no previous randomized controlled trials on this study product were available. The sample size was determined. Pocket probing depth was taken into account, with an expected difference of 0.82mm and a standard deviation of 0.61mm. It was calculated that 10 patients were needed in each group to provide 80% power with an alpha of 0.05 . Despite this low number and taking into consideration studies comparing the adjunctive effect of antibiotics to scaling and rootplaning, it was decided to include 24 patients in each group.
Randomization of the patients was done by block randomization . The study coordinator distributed the coded bottles to the examiner at baseline, 4 weeks and 8 weeks visit. Except for the study coordinator, all patients and study personnel were blinded to the study group allocation. Before sending the data to the biostatistician, the code was broken to group the patients to the proper groups.
Treatment protocol Patients fulfilling the eligibility criteria were asked to participate in the study and after approval to sign an informed consent. Baseline examination included full-mouth probing pocket depth , gingival recession and bleeding on probing measured at six sites per tooth. Additionally the plaque en gingival indexes were noted. The full-mouth plaque index was recorded.After baseline periodontal examination and microbial analysis, an oral hygiene instruction was given (toothbrush, interdental brush). Initial periodontal therapy consisted of a full-mouth one-stage disinfection approach . All clinical procedures were performed by the same periodontist . The patient was asked to rinse for 2 minutes with a 0.12% chlorhexidine solution without alcohol . Scaling and rootplaning were performed on 2 consecutive days using an ultrasonic scaler under 0.12% chlorhexidine irrigation and with hand instruments. All mucosal surfaces were afterwards disinfected and the tongue was brushed for 1 minute. Besides, the participants were randomized over the 2 treatment groups: control or probiotic group.The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months. The participants in the control group were asked to do the same with a placebo tablet. All patients were instructed to use the tablets after brushing their teeth in the morning and in the evening. The probiotic and placebo tablets were identical in shape, texture, taste and composition except that Streptococcus were added for the probiotic tablet. All patients were supplied with the same toothpaste . It was asked not to use any probiotic containing products during the course of the study. Neither was it allowed to use drugs with anti-inflammatory properties, chlorhexidine or other mouthrinses during the study.
At designated time points, follow-up visits were planned. 30 days and 60 days after initiation of the therapy clinical evaluation and microbial analysis were performed. 90 days and 180 days after the initial treatment all baseline parameters were recorded .
Outcomes variables of interest Primary outcome measures The primary response variable was Probing pocket depth. All examinations were performed with a North Carolina periodontal probe .
Secondary outcome measures The secondary response variables were recession, clinical attachment level , Bleeding, Gingival index, Plaque index and microbial parameters.
Sub-analyses were performed on these outcome variables taking into account the initial Pocket. A pocket was considered moderate if its initial Pocket was between 4 and 6 mm and deep if ≥7 mm. "Risk for disease progression" was defined at patient level. The "need for surgery" outcome measure was calculated. A site was considered as "in need for surgery" if the Pocket was ≥6 mm or 5 mm and Bleeding positive. A tooth was considered in need for surgery if it had at least one site in need for surgery. A patient was considered in need or surgery if at least one tooth was in need for surgery.
Microbiological samples were collected of supragingival and subgingival plaque, saliva and the tongue. Pooled supragingival plaque samples were taken with the aid of curettes at the four single-rooted teeth with the deepest initial pocket in each quadrant. Before sampling, the sites were isolated from saliva with the aid of cotton rolls and then dried with compressed air. All supragingival plaque from these sites was dispersed. Samples were dispersed using a vortex mixer and immediately frozen at -20°C until analysis. On the same teeth pooled subgingival plaque samples were collected per site. After 10 s, the samples were transferred to a sterile Eppendorf tube, as described Saliva samples were obtained by collecting unstimulated saliva in a sterile cup. Finally the biofilm of the tongue was collected with a cotton swab. These were wiped 10 times over the tongue starting from the tongue dorsum.
Processing of the microbial samples After finishing the study, the frozen samples were send on dry ice to the department of Periodontology , these were immediately frozen at -80°C upon arrival. each sample was later defrosted and centrifuged at 13.000g. Bacterial DNA was extracted . A quantitative assay was performed to quantify certain bacteria.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| probiotic | Active comparator | Dietary Supplement: probioticThe participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months. |
| placebo | Placebo comparator | Dietary Supplement: placeboThe participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- healthy, non-institutionalized male or female patients,
- at least 35 years of age,
- a minimum of 3 natural teeth in every quadrant and
- previously untreated moderate to severe periodontitis
Key exclusion criteria (5 listed)
- received antibiotics for any purpose within 6 months prior to entering the study or suffering from a disease condition that would typically require antibiotic prophylaxis before dental treatment,
- a history of diabetes, rheumatic fever, liver or kidney disease, neurological deficiencies, or use of medication which may affect periodontal tissue (for example: phenytoin, cyclosporin, chronic use of non-steroidal anti-inflammatory drugs),
- pregnancy,
- acute oral lesions or necrotizing ulcerative periodontitis and
- dental personnel
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| probioticthe patients used probiotic tablets in addition to scaling and root planning | Dietary supplement | probiotic |
| placebothe patients used placebo tablets in addition to scaling and root planning | Dietary supplement | placebo |
Primary outcome
probing pocket depth
Time frame: 24 weeks
6 secondary outcomes
Recession
Time frame: 24 weeks
clinical attachment level
Time frame: 24 weeks
Bleeding on probing
Time frame: 24 weeks
Gingival Index
Time frame: 24 weeks
Plaque Index
Time frame: 24 weeks
microbial counts of bacteria
Time frame: 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2015.
- Derived from this study: PubMed 26427036Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, Slomka V, Quirynen M, Alkaya B, Teughels W. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015 Nov;42(11):1032-41. doi: 10.1111/jcpe.12464. Epub 2015 Nov 29.
Related trials for Periodontitis
Recruiting
Effect of Ultrasonic and Diode Laser Activated Irrigation on Postoperative Pain Following Root Canal Treatment
Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Cohort Study on the Non-Surgical Treatment of Periapical Inflammatory Lesions With Vitapex Paste
Periapical Periodontitis, Periapical Abscess
RecruitingObservational study
Characterization of Small Intestinal Bacterial Overgrowth and Intestinal Barrier-Related Biomarkers in Patients With Severe Periodontitis: A Pilot Prospective Longitudinal Observational Cohort Study
Periodontitis (Stage 3), Periodontitis Stage IV
Not yet recruiting
Post-operative Pain and Apical Healing After Root Canal (re)Treatment With Laser-activated Irrigation Versus Sonic or no Activation
Apical Periodontitis, Post Operative Pain, Acute
Active, not recruitingObservational study
Evaluation of MTHFR and DNMT3B Gene Polymorphisms Along With Periodontal Clinical Parameters in Healthy Individuals and Individuals With Type 2 Diabetes and Periodontitis
Periodontitis, Type 2 Diabetes Mellitus (DM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Onur Ozcelik study chair
CU
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing probiotic in people with Periodontitis, run by Cukurova University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
probing pocket depth (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02403960, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2015.